{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:35:49Z","timestamp":1773866149768,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease with a significant impact on health. Appropriate treatment requires effective and timely escalation to achieve metabolic control. To evaluate the effectiveness and safety of IDegLira on adults with T2DM previously treated with oral antidiabetics and\/or insulin in a real-life setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational study in a real-world setting was conducted. Patients were selected from the outpatient clinic of two centers dedicated to specialized diabetes care. Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and other adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>67 T2DM patients treated with IDegLira were monitored between 3 and 7 months. At the end of foll ow-up, the median change in HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This real-life study shows the effectiveness in glycemic control of IDegLira use in T2DM patients who do not achieve goals with other therapies, with an adequate safety profile. The findings need to be confirmed with evaluation of therapeutic results in larger cohorts.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.828607","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T15:46:51Z","timestamp":1651160811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting"],"prefix":"10.3389","volume":"13","author":[{"given":"Alex","family":"Ram\u00edrez-Rinc\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Builes-Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime A.","family":"Hincapi\u00e9-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 F.","family":"Botero-Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-020-00559-7","article-title":"Clinical Inertia is the Enemy of Therapeutic Success in the Management of Diabetes and its Complications: A Narrative Literature Review","volume":"12","author":"Andreozzi","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","article-title":"Clinical Inertia to Insulin Initiation and Intensification in the UK: A Focused Literature Review","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.metabol.2010.09.010","article-title":"Management of Type 2 Diabetes: Evolving Strategies for the Treatment of Patients With Type 2 Diabetes","volume":"60","author":"Nyenwe","year":"2011","journal-title":"Metabolism"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2010.03.001","article-title":"Insulin Initiation in Primary Care for Patients With Type 2 Diabetes: 3-Year Follow-Up Study","volume":"4","author":"Dale","year":"2010","journal-title":"Prim Care Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S116810","article-title":"Comparative Effectiveness of Glycemic Control in Patients With Type 2 Diabetes Treated With GLP-1 Receptor Agonists: A Network Meta-Analysis of Placebo-Controlled and Active-Comparator Trials","volume":"10","author":"Orme","year":"2017","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"B6","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION. XULTOPHY\u00ae 100\/3.6 (Insulin Degludec and Liraglutide Injection)2019"},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/DMSO.S27528","article-title":"Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy to Basal Insulin in Patients With Type 2 Diabetes: A Systematic Review","volume":"5","author":"Berlie","year":"2012","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.2016.1252","article-title":"Effect of Insulin Glargine Up-Titration vs Insulin Degludec\/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial","volume":"315","author":"Lingvay","year":"2016","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1114","article-title":"Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial","volume":"41","author":"Billings","year":"2018","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0673-8","article-title":"Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes","volume":"10","author":"Zoltan","year":"2019","journal-title":"Diabetes Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13182","article-title":"Use and Effectiveness of a Fixed-Ratio Combination of Insulin Degludec\/Liraglutide (IDegLira) in a Real-World Population With Type 2 Diabetes: Results From a European, Multicentre, Retrospective Chart Review Study","volume":"20","author":"Hermione","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.endmts.2020.100057","article-title":"IRWIS (IDegLira Real World Indian Study): A Real-World Observational Study For Use of IDegLira In Indian Patients","volume":"1","author":"Gangopadhyay","year":"2020","journal-title":"Endocr Metab Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2018.06.029","article-title":"Real-World Clinical Experience of Xultophy in the Management of Patients With Type 2 Diabetes in a Secondary Care Clinic","volume":"12","author":"Williams","year":"2018","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3","article-title":"Efficacy and Safety of a Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Compared With its Components Given Alone: Results of a Phase 3, Open-Label, Randomised, 26-Week, Treat-To-Target Trial in Insulin-Naive Patients With Type 2 Diabetes","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0218-3","article-title":"The Efficacy of IDegLira (Insulin Degludec\/Liraglutide Combination) in Adults With Type 2 Diabetes Inadequately Controlled With a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial","volume":"8","author":"Linjawi","year":"2017","journal-title":"Diabetes Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13256","article-title":"Treatment Safety and Efficacy of Insulin Degludec\/Liraglutide (IDegLira) Added to Sulphonylurea Alone or to Sulphonylurea and Metformin in Insulin-Na\u0131ve People With Type 2 Diabetes: The DUAL IV Trial","volume":"34","author":"Rodbard","year":"2016","journal-title":"Diabet Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12892","article-title":"Safety and Efficacy of IDegLira Titrated Once Weekly Versus Twice Weekly in Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Randomized Clinical Trial","volume":"19","author":"Harris","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S2213-8587(19)30184-6","article-title":"Durability of Insulin Degludec Plus Liraglutide Versus Insulin Glargine U100 as Initial Injectable Therapy in Type 2 Diabetes (DUAL VIII): A Multicentre, Open-Label, Phase 3b, Randomised Controlled Trial","volume":"7","author":"Aroda","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13666","article-title":"Superior Efficacy of Insulin Degludec\/Liraglutide Versus Insulin Glargine U100 as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: A Randomized Clinical Trial in People With Uncontrolled Type 2 Diabetes","volume":"21","author":"Philis-Tsimikas","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00850-w","article-title":"Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice","volume":"11","author":"Egede","year":"2020","journal-title":"Diabetes Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198403293101307","article-title":"Development of Diabetic Complications Despite the Absence of Growth Hormone in a Patient With Post-Pancreatectomy Diabetes","volume":"310","author":"Radin","year":"1984","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00725-9","article-title":"Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting","volume":"11","author":"Melzer-Cohen","year":"2020","journal-title":"Diabetes Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1925","article-title":"Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-Analysis","volume":"40","author":"Khunti","year":"2017","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2147\/PPA.S136639","article-title":"Cost of Medication Adherence and Persistence in Type 2 Diabetes Mellitus: A Literature Review","volume":"11","author":"Kennedy-Martin","year":"2017","journal-title":"Patient Prefer Adherence"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.828607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T15:46:54Z","timestamp":1651160814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.828607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":24,"alternative-id":["10.3389\/fendo.2022.828607"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.828607","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"828607"}}